Prof Rafael Carazo Salas is a Professor at the University of Bristol’s School of Cellular and Molecular Medicine and the CEO and founder of CellVoyant.
CellVoyant aims to enable the cost-effective, reliable, and rapid development of new cell therapies, by combining advanced AI with live cell imaging to help scientists understand the composition of cells and anticipate how they will evolve.
Prior to his current roles, Rafael worked at the EMBL Heidelberg, Cancer Research UK, Rockefeller University, the Institute of Biochemistry in Zurich, and the Gurdon Institute in Cambridge.